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Abstract
Per- and polyfluoroalkyl substances (PFAS) have been widely used in commercial and industrial 
manufacturing processes since the 1950s. Inverse associations between prenatal exposure to PFAS 
and birth size have been found in populations around the globe. This study examined the 
association of prenatal maternal serum concentrations of perfluorooctane sulfonic acid (PFOS), 
perfluorooctanoic acid (PFOA), perfluorohexane sulfonic acid (PFHxS), and perfluorononanoic 
acid (PFNA) and birth size in British boys. The study included 457 mother-son dyads participating 
in the Avon Longitudinal Study of Parents and Children (ALSPAC). Birth weight (g), crown to 
heel length (cm), and head circumference (cm) were collected at delivery. PFAS were detected in 
all maternal serum samples during pregnancy (median: 30 weeks gestation (interquartile range: 
12–33)). Median concentrations (interquartile range) were 13.8 ng/mL (11.0, 17.7), 3.0 ng/mL 
(2.3, 3.8), 1.9 ng/mL (1.4, 2.5), and 0.4 ng/mL (0.3, 0.5) for PFOS, PFOA, PFHxS, and PFNA, 
respectively. In multivariable linear regression models, inverse associations were detected between 
PFOS (continuous) and birth weight (β = −8.50 g, 95% CI = −15.93, − 1.07 g), crown to heel 
length (β = −0.04 cm, 95% CI = −0.08, −0.01 cm), and head circumference (β = − 0.02 cm, 95% 
CI = − 0.04, −0.002 cm). In conclusion, prenatal exposure to high levels of PFOS may be 
associated with reduced birth size in male infants.
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1. Introduction
Perfluorinated compounds are organic substances characterized by a long chain of carbon-
fluorine bonds with unique stability and extremely low surface tension (Giesy and Kannan, 
2001; Paul et al., 2009; Wang et al., 2009). Per- and polyfluoroalkyl substances (PFAS) are 
highly stable in the environment. The low surface tension allows PFAS to repel dirt, water, 
and oil. As a result, they are commonly used as surfactants in textiles, footwear, furniture, 
carpets, lubricants, waxes, fire-fighting foam, and nonstick coatings (Giesy and Kannan, 
2001; Paul et al., 2009; Wang et al., 2009). PFAS have been found in water, sediment, soil, 
and wildlife across the globe (Jensen and Leffers, 2008). The long fluorinated chain does not 
degrade in the environment or in humans (Lau et al., 2007).
Exposure to PFAS is ubiquitous and occurs through water, food, and indoor air (Agency for 
Toxic Substances Disease Registry, 2009). Common perfluoroalkyl acids include 
perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), perfluorohexane 
sulfonic acid (PFHxS), and perfluorononanoic acid (PFNA), though a number of forms have 
been phased out. PFAS are lipophilic and hydrophobic (DeWitt, 2015), thus readily bind to 
proteins in blood. As a result, they accumulate in the blood, kidneys, liver, and spleen over 
long periods of exposure (Olsen et al., 2007). Half-lives in human serum are approximately 
2–4 years for PFOA, 3–6 years for PFOS, and 8–16 years for PFHxS (Bartell et al., 2010; 
Olsen et al., 2007; Worley et al., 2017; Zhang et al., 2013b). Data on the half-life of PFNA 
are limited, though findings to date suggest that PFNA is more persistent in humans than 
PFOA (Zhang et al., 2013a). PFAS are readily transferred to the fetus through the placenta 
(Apelberg et al., 2007a).
Several animal studies have suggested that prenatal PFAS exposure can influence fetal 
growth; specifically, prenatal PFOS and PFOA exposure can reduce birth weight and 
gestational age at delivery among rodents (Lau et al., 2004, 2006; Luebker et al., 2005). A 
number of potential mechanisms have been posited, including a disturbance of lipid and 
glucose homeostasis, suppression of primary antibody responses, altered glucocorticoids and 
reproductive hormone levels, or effects on cell proliferation and differentiation (DeWitt et 
al., 2012; Goudarzi et al., 2017; Yang et al., 2002).
The epidemiological literature on prenatal PFAS exposure and birth size (birth weight, birth 
length, and head circumference) has been mixed, with some studies finding that higher 
concentrations are associated with reduced birth size (Apelberg et al., 2007b; Chen et al., 
2012; Fei et al., 2007; Maisonet et al., 2012; Meng et al., 2018; Minatoya et al., 2017; Sagiv 
et al., 2018; Starling et al., 2017), while others observe largely null associations (Ashley-
Martin et al., 2017; Hamm et al., 2010; Manzano-Salgado et al., 2017; Shoaff et al., 2018; 
Whitworth et al., 2012; Woods et al., 2017), with inconsistent results across PFAS 
chemicals. To date, studies of PFAS exposure and birth size have been conducted in 
American, Canadian, Danish, Norwegian, Spanish, Japanese, and Taiwanese populations. 
While the aforementioned are examples of relevant studies, there are also published 
systematic reviews/meta-analyses on the topic (Bach et al., 2015; Johnson et al., 2014; 
Steenland et al., 2018). In particular, an updated meta-analysis with bias analysis of serum 
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PFOA and birth weight concluded that human evidence provides only modest support for 
lower birth weight with higher maternal PFOA concentrations (Steenland et al., 2018).
The Avon Longitudinal Study of Parents and Children (ALSPAC) is an ongoing prospective 
birth cohort of British children. Previous research has shown that maternal serum 
concentrations of PFOS, PFOA, and PFHxS during pregnancy are inversely associated with 
birth size in ALSPAC girls (Maisonet et al., 2012). Studies have found that exposure to 
PFAS can affect the functioning of both androgen and estrogen receptors in utero (Kjeldsen 
and Bonefeld-Jørgensen, 2013). Because sex hormones have differential roles by gender on 
fetal development, PFAS may therefore have differential effects on fetal development. Thus, 
this study aimed to assess the association between maternal serum concentrations of PFOS, 
PFOA, PFHxS, and PFNA with birth weight, crown to heel length, and head circumference 
in infant males, in mother-son dyads from the ALSPAC cohort.
2. Methods
2.1. Study population
ALSPAC recruited pregnant women with expected delivery dates between April 1st, 1991 
and December 31st, 1992. The study enrolled 14,541 pregnant women and their children 
from three health districts of the former Avon region in South West England. Recruitment 
methods have been described elsewhere (Boyd et al., 2013; Fraser et al., 2013). Enrolled 
mothers and children provided biological samples, completed questionnaires, and 
participated in clinical assessments.
The present study uses a subset of data to study the association between prenatal endocrine 
disrupting chemical exposure and growth and development in boys. The subset was selected 
to maximize data on puberty and dual energy X ray absorptiometry (DXA) scans. At the 
time maternal serum samples were analyzed for PFAS concentrations, there were 457 
mother-son dyads who had maternal serum samples collected during pregnancy as well as 
two or more completed puberty questionnaires before the age of 13 (five questionnaires 
possible, starting at age 8) and two or more DXA scans for sons (five DXA scans possible, 
starting at age 9).
Please note that the study website contains details of all the data that is available through a 
fully searchable data dictionary and variable search tool (http://www.bris.ac.uk/alspac/
researchers/our-data/). We obtained ethical approval for the study from the ALSPAC Ethics 
and Law Committee, the Local Research Ethics Committees, and the Centers for Disease 
Control and Prevention (CDC) Institutional Review Board. Mothers provided written 
informed consent for participation in the study.
2.2. Exposure assessment
The following PFAS were included in this analysis: PFOA, PFOS, PFHxS, and PFNA. 
Maternal serum samples were collected at median 30 weeks gestation (interquartile range 
(IQR): 12–33 weeks). Maternal serum samples were held in storage facilities at the 
University of Bristol until they were transferred under controlled conditions to the National 
Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention 
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(CDC) in the United States for analysis in 2015. Samples were analyzed by on-line solid-
phase extraction coupled to isotope dilution high-performance liquid chromatography-
tandem mass spectrometry (Kato et al., 2011a). The limit of detection was 0.10 ng/mL for 
all PFAS under study. There were no samples below the limit of detection. Serum 
concentrations of PFAS are considered to be relatively stable throughout pregnancy (Fei et 
al., 2007), therefore the earliest available serum sample was chosen in the event that multiple 
samples were available.
2.3. Outcome assessment
Birth weight (g) was abstracted from infant medical records. Trained ALSPAC staff 
measured crown to heel length (cm) using a Harpenden neonatometer (Holtain Ltd.) and 
head circumference (cm) using a lasso tape measure within 24 h of birth (median 1 day, 
range: 1–14 days). Additional details on birth size measurement and quality control are 
described elsewhere (Dunger et al., 1998; Taylor et al., 2016).
2.4. Covariates
Potential confounders were identified a priori based on previously published literature and 
biological plausibility. Potential confounders were factors known to be associated with birth 
size as well as PFAS body burden, but not on the causal pathway between PFAS and birth 
size. We considered the following as covariates: maternal weight gain during pregnancy 
(kg), maternal age at delivery (years), maternal pre-pregnancy BMI (kg/m2), maternal 
education (classified as < O-level [ordinary level: required, completed at age 16], O-level, or 
> O-level), vitamin use or folic acid use during pregnancy (yes/no), smoking during 
pregnancy (yes/no), alcohol use during pregnancy (yes/no), parity (nulliparous/multiparous), 
and gestational age at sample collection (weeks). Clinical staff documented maternal age 
and gestational age at sample collection, while the remainder of the covariates were self-
reported on questionnaires completed by the mother during or immediately after pregnancy.
2.5. Statistical analyses
All analyses were conducted in SAS 9.4 (Cary, NC, USA). Descriptive analyses were 
conducted for each PFAS. Kruskal-Wallis and Wilcoxon Rank Sum tests were utilized to test 
for differences in PFAS concentrations between tertiles of birth size measures (birth weight, 
crown to heel length, head circumference) and to compare median PFAS values for each 
level of the covariates.
A set of potential confounding variables was identified a priori for consideration in 
multivariable linear regression models used to separately estimate the association between 
prenatal PFAS concentrations and birth weight, head circumference, and crown to heel 
length. Full multivariate models assessed confounding by maternal weight gain, maternal 
age, maternal pre-pregnancy BMI, maternal education, vitamin use, folic acid use, smoking 
during pregnancy, alcohol use during pregnancy, parity, and gestational age at sample 
collection, as well as interaction terms between PFAS and maternal BMI, parity, and 
education. There were no significant interaction terms. The final model was selected after 
removing covariates from the full model that did not satisfy our a priori change-in-estimate 
criterion of 10%.
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Two sensitivity analyses were conducted. First, given the range of PFAS concentrations, 
PFAS were analyzed as quintiles (in addition to tertiles) to better detect nonlinear 
associations. Second, analyses were repeated in a subset of mother-son dyads with blood 
sampled during the first trimester (≤ 12 weeks).
3. Results
In this subset of the ALSPAC cohort, boys were predominantly born to normal weight (18.5 
≤ BMI < 25) (72.7%) mothers under the age of 35 (88.1%) who had attained at least 
ordinary levels (O-levels) of education (78.5%) (Table 1). A slight majority of mothers was 
multiparous (52.0%) and the vast majority did not smoke (90.0%) or drink alcohol (85.7%) 
during pregnancy. Maternal serum PFAS concentrations were strongly correlated with one 
another; PFOA and PFOS (r = 0.63) and PFOS and PFNA (r = 0.60) were most strongly 
correlated (Table S1). Of the four PFAS assessed, PFOS was present at the highest 
concentrations in serum (median: 13.8 ng/mL, IQR: 11.0, 17.7 ng/mL) (Table 1). 
Concentrations of all four PFAS under study were higher among nulliparous women and 
among women with serum samples taken in the first 20 weeks of pregnancy, but there were 
no other strong associations between PFAS and maternal characteristics. There was some 
evidence that mothers who reported taking folic acid had higher PFAS concentrations than 
those who did not. Univariate results generally showed an inverse association between 
tertiles of birth size and PFAS, although this was only significant for PFOS and birth weight. 
Maternal PFOS concentrations were highest for infants with the lowest birth weight (14.4 
ng/mL for those < 3290 g versus 13.2 ng/mL for those > 3720 g).
In adjusted models, results were attenuated but PFOS remained inversely associated with 
birth weight (Table 2). A 1-ng/mL higher PFOS level was associated with a −8.50 g (95% 
confidence interval (CI): −15.93, −1.07 g) lower birth weight. In adjusted models where 
PFAS concentrations were categorized into tertiles of exposure, there were weak inverse 
associations between PFNA with birth weight. Infants in the highest tertile (tertile 3) of 
PFNA exposure weighed −133.02 g less than those in the lowest tertile of PFNA exposure 
(95% CI: −265.41, −0.64 g; p-trend: 0.06). Similar results were observed when quintiles of 
PFAS exposure were used as opposed to tertiles in sensitivity analyses (Table S2).
In multivariable models, PFOS was inversely associated with crown to heel length and 
marginally associated with head circumference (Table 2). A 1-ng/mL higher PFOS was 
associated with a −0.04 cm (95% CI: −0.08, −0.01 cm) lower crown to heel length. A 1-
ng/mL higher PFOS was associated with a mean difference in head circumference of −0.02 
cm (95% CI: −0.04, −0.002 cm). There was some evidence of similar inverse associations 
between PFHxS and PFNA and crown to heel length and head circumference. In adjusted 
models where PFAS concentrations were categorized into tertiles of exposure, there were 
suggestions of inverse associations between PFOS and head circumference. Compared to 
those in the lowest tertile of PFOS exposure, the mean difference in head circumference was 
−0.25 cm (95% CI: −0.58, 0.07 cm) for infants in the highest tertile of exposure.
In our sensitivity analysis, we examined those (n = 115) with blood sampled in the first 
trimester (≤12 weeks). The associations between all PFAS and birth weight were null but in 
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the same direction as was observed for the entire study sample across all four PFAS of 
interest. Among those with blood sampled in the first trimester, a 1-ng/mL higher PFOS 
level was associated with a −8.95 g (95% CI = −25.53, 7.63 g) lower birth weight (data not 
shown).
4. Discussion
Evidence from animal and human studies suggests that prenatal exposure to PFAS may have 
adverse effects on fetal growth. We explored associations of maternal serum concentrations 
of PFOS, PFOA, PFHxS, and PFNA during pregnancy with birth size (birth weight, crown 
to heel length, and head circumference) in a sample of British boys. We found that higher 
prenatal PFOS concentrations were associated with lower birth weight, shorter crown to heel 
length, and smaller head circumference. While differences may not be considered large at 
the individual or clinical level, it is important to consider implications at the population 
level. A relatively modest and subclinical effect size may be associated with substantial 
population burden if the exposure is prevalent (Bellinger, 2012; Johnson et al., 2014), like 
PFAS.
Inverse associations of prenatal PFOS concentrations with birth size were found in both the 
present study and among girls in the same cohort (Maisonet et al., 2012). PFOS was 
associated with lower birth weight and shorter crown to heel length for both sexes of infants. 
PFOA and PFHxS were associated with reduced birth weight among the ALSPAC girls 
cohort, but not among boys, though the direction of the association is consistent, suggesting 
considerable interaction by sex is unlikely. Previous studies have examined the association 
of PFAS and birth size by infant sex, and most did not report differences by infant sex. Three 
studies found no interaction (Sagiv et al., 2018; Shoaff et al., 2018; Starling et al., 2017), 
while another study found interaction by sex only when examining dichotomous outcomes 
like low birth weight (Manzano-Salgado et al., 2017). Overall, the literature to date suggests 
PFAS may have little differential effect on fetal development by sex.
Outside of the ALSPAC cohort, our weakly inverse or null results are consistent with those 
reported in other epidemiologic studies of PFAS and birth size. The PFAS concentrations in 
this study are generally similar to levels reported in previous studies (Apelberg et al., 2007b; 
Ashley-Martin et al., 2017; Chen et al., 2012; Fei et al., 2007; Hamm et al., 2010; Manzano-
Salgado et al., 2017; Meng et al., 2018; Minatoya et al., 2017; Sagiv et al., 2018; Shoaff et 
al., 2018; Starling et al., 2017; Whitworth et al., 2012; Woods et al., 2017), though PFNA is 
lowest in the present study. Studies from Japan (n = 168) (Minatoya et al., 2017), the United 
States (Maryland) (n = 299) (Apelberg et al., 2007b), Denmark (n = 1,400) (Fei et al., 2007), 
and Taiwan (n = 429) (Chen et al., 2012) have found evidence of inverse associations of 
PFOA and PFOS with birth size. An American study (Massachusetts) (n = 1,645) found a 
weakly inverse association of maternal PFNA with birth weight (Sagiv et al., 2018). A third 
American study (Ohio) (n = 272) analyzed PFAS as a class using Bayesian Hierarchical 
Linear Models and found that for a 10-fold increase in chemical concentration, the mean 
difference in birth weight was −11 g for PFAS (Woods et al., 2017). Finally, as we observed 
in our study for PFOA, PFHxS, and PFNA, other studies have found some evidence of 
modestly inverse or null associations between PFAS and birth weight (Ashley-Martin et al., 
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2017; Hamm et al., 2010; Manzano-Salgado et al., 2017; Shoaff et al., 2018; Whitworth et 
al., 2012).
A 2014 meta-analysis by Johnson et al. examined PFOA and birth size and estimated a 19-g 
reduction in birth weight with each 1 ng/mL increase in maternal serum PFOA 
concentrations (Johnson et al., 2014). Estimates for length (−0.06 cm per 1 ng/mL increase) 
and head circumference (−0.03 cm per 1 ng/mL increase) were also reported. While our null 
or slightly positive estimates of PFOA as a continuous variable are not similar in effect size 
to the values reported in this meta-analysis, our effect estimates for the third tertile of PFOA 
exposure suggest that higher PFOA exposure is associated with smaller birth size outcomes. 
When quintile of PFOA exposure was examined in relation to birth weight, estimates for all 
quintiles except the fourth quintile were null but slightly positive. Infants in the fourth 
quintile of PFOA exposure weighed −56.63 g less than those in the lowest quintile of PFOA 
exposure (95% CI: (−215.17, 101.92 g). These findings may suggest that the association 
between PFOA and birth size outcomes is not linear in our population. The shape of the 
association (linear or nonlinear) of PFAS and birth size is unresolved and leads to questions 
about the use of meta-analyses, particularly with higher concentrations of PFAS (Food 
Standards Australia New Zealand (FSANZ), 2017).
Of the four PFAS under study, PFOS is typically found in the highest concentration in 
humans, but it has declined over the last two decades (Kato et al., 2011b). In contrast, PFNA 
levels have been on the rise, which is thought to be related to the degradation of volatile 
fluorotelomer alcohols, which are used in stain repellents (Kato et al., 2011b). While PFOS 
had a stronger association with birth size than PFNA in the ALSPAC cohort from the early 
1990s, it is possible that the higher PFNA levels found today would imitate the effect of 
PFOS in the 1990s. The latter was seen in the Massachusetts study, which took place a 
decade later and found a weakly inverse association of maternal PFOS and PFNA with birth 
weight (Sagiv et al., 2018).
We compared PFAS concentrations in ALSPAC to levels in adult females of the National 
Health and Nutrition Examination Survey (NHANES) in the United States in the late 1990s 
(closest NHANES measurements to ALSPAC collection) and into the mid-2010s (most 
recent NHANES measurements) (Table S3) (Centers for Disease Control and Prevention, 
2017). Concentrations in ALSPAC mothers were similar though slightly lower than 
NHANES 1999–2000 levels. As expected given the temporal trends of PFAS exposure, 
PFAS concentrations in ALSPAC mothers were higher than 2015–2016 NHANES 
concentrations, with the exception of PFNA. For additional context, a comparison of 
maternal serum concentrations of PFAS in European and Asian cohorts has been published 
previously (Bjerregaard-Olesen et al., 2017). ALSPAC PFOA and PFOS geometric mean 
concentrations were within the range of concentrations observed in these Scandinavian and 
Chinese cohorts (which took place between 1996 and 2015) ( Table S3). ALSPAC PFHxS 
concentrations were higher while PFNA concentrations were lower than concentrations 
observed in European and Asian cohorts (Bjerregaard-Olesen et al., 2017).
This study benefitted from a large sample size, prospective design, and reliable biological 
measure of four PFAS. However, we note a few limitations. Self-reported smoking and 
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alcohol use during pregnancy are often unreliable, and these measures may suffer from 
social desirability bias. Education was the only proxy for socioeconomic status used in this 
analysis because many women did not report income. Environmental factors linked to 
income, including housing, water contamination, occupational exposure, and diet can 
increase both the likelihood of PFAS exposure and decreased birth size. Therefore, it is 
possible that there is residual confounding by income.
Another limitation is that the sub-sample used in this study differed from the overall 
ALSPAC cohort on some factors. For example, mothers in our sample were more likely to 
be white, highly educated, older, and nonsmokers than mothers in the overall ALSPAC 
cohort (data not shown). These differences are unsurprising given that to be selected for this 
sub-sample, children still had to be engaged with the study during puberty (completing two 
or more puberty questionnaires) and to have completed two or more DXA scans, which 
required a clinic visit. Generally, nonparticipation and loss to follow-up tends to be more 
pronounced among the less advantaged and less healthy (Barchielli and Balzi, 2002; 
Goldberg et al., 2001; Heilbrun et al., 1982; Knudsen et al., 2010; Reilly and Kelly, 2011; 
Strandberg et al., 1995; Strandhagen et al., 2010; Wilhelmsen et al., 1976).
Lastly, there is some concern about reverse causality and confounding, because the outcome 
of interest may affect the measured biomarker level and there may be shared biological 
determinants of the exposure measure and pregnancy outcome (e.g., hemodynamics), 
respectively (Savitz, 2014). Previous studies have shown that reverse causality and 
confounding are less of a concern when there is a wide range of exposure and when blood 
samples are collected early in pregnancy (Sagiv et al., 2018; Steenland et al., 2018). To 
address such concerns in our study, we adjusted for gestational age (in weeks) of sample 
collection. We also conducted a sensitivity analysis examining only those (n = 115) with 
blood sampled in the first trimester (≤12 weeks). In our sensitivity analysis, the associations 
between all PFAS and birth weight were null (potentially due to a lack of power), but in the 
same direction as was observed for the entire study sample across all four PFAS of interest. 
Specifically, the association of PFOS with birth weight was strikingly similar, although less 
precise, among those with blood collected in the first trimester (β = −8.95, 95% CI = 
−25.53, 7.63g) compared to the entire study sample (β = −8.50, 95% CI = −15.93, −1.07 g). 
This sensitivity analysis suggests that reverse causality and confounding may not be a 
substantial concern in our study.
In conclusion, British boys born to mothers with higher serum concentrations of PFOS 
during pregnancy appear to weigh less, have a shorter crown to heel length, and a smaller 
head circumference at birth. Other PFAS under study also showed some evidence of inverse 
associations with birth size outcomes.
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